HPK1-IN-71

HPK1-IN-71 (compound D5) (0.11-1 μM; pretreatment for 30min + co-incubation with CD3/CD28 for 24h) leads to a modest yet statistically significant enhancement of IL-2 secretion at 0.33 μM, whereas the IL-2 stimulatory effect is diminished at 1 μM in primary mouse T cells^[1].
HPK1-IN-71 (0-10 μM pretreatment for 2h + co-incubation with anti-CD3/CD28 antibodies for 10 min) leads to aconcentration-dependent reduction in SLP76 phosphorylation in Jurkat cells with significant inhibition at 1 μM and 10 μM^[1].
HPK1-IN-71 (0-100 μM; 72 h) displays low cytotoxicity in Jurkat cells IC₅₀= 63.00 μM)^[1].
HPK1-IN-71 (1 μM; pretreatment for 60min + co-incubation with ADP-Glo™ reagent for 40min) only inhibits CDK2 and MST1 with > 80% inhibition, while exhibiting 50%-80% inhibition against just six other kinases. HPK1-IN-71 demonstrates high selectivity over LCK, IKKα and TAK1, all of which are directly involved in TCR signaling. HPK1-IN-71 displays moderate inhibition of GCK (MAP4K2), KHS (MAP4K5) and GLK (MAP4K3) with all inhibition rates below 80%. HPK1-IN-71 demonstrates a high degree of selectivity towards HGK (MAP4K4), MINK (MAP4K6) and all tested immune-related tyrosine kinases ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.